Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joincare Pharmaceutical Group Industry Co's EBIT per Share for the
three
months ended in Mar. 2026 was ¥0.58.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥1.85.
During the past 12 months, the average EBIT per Share Growth Rate of Joincare Pharmaceutical Group Industry Co was -8.80% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 0.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 5.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 12.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
SHSE:600380'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -10.3 Med: 13.4 Max: 80.6
Current: 0.1
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Joincare Pharmaceutical Group Industry Co was 80.60% per year. The lowest was -10.30% per year. And the median was 13.40% per year.
SHSE:600380's 3-Year EBIT Growth Rate is ranked worse than 62.32% of 812
companies
in the Drug Manufacturers industry
Industry Median: 7.55
vs SHSE:600380: 0.10
Joincare Pharmaceutical Group Industry Co (SHSE:600380) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Joincare Pharmaceutical Group Industry Co EBIT per Share Related Terms
Joincare Pharmaceutical Group Industry Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joincare Pharmaceutical Group Industry Co EBIT per Share Chart
Joincare Pharmaceutical Group Industry Co Annual Data
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.85
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joincare Pharmaceutical Group Industry Co (SHSE:600380) has a EBIT per Share of ¥1.85 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Joincare Pharmaceutical Group Industry Co and its competitors. According to the industry distribution chart, Joincare Pharmaceutical Group Industry Co ranks #506 out of 812 companies in the Drug Manufacturers industry, placing it in the top 62.3%.
Is Joincare Pharmaceutical Group Industry Co's EBIT per Share too high?
Joincare Pharmaceutical Group Industry Co's current EBIT per Share is ¥1.85. Based on the distribution chart, Joincare Pharmaceutical Group Industry Co ranks #506 out of 812 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Joincare Pharmaceutical Group Industry Co has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Joincare Pharmaceutical Group Industry Co's EBIT per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Joincare Pharmaceutical Group Industry Co ranks #506 out of 812 companies for EBIT per Share. This places Joincare Pharmaceutical Group Industry Co in the lower half of its industry. The industry median EBIT per Share is 7.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.55, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Joincare Pharmaceutical Group Industry Co and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Joincare Pharmaceutical Group Industry Co's current EBIT per Share is ¥1.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joincare Pharmaceutical Group Industry Co stock overvalued right now?
Based on GuruFocus' analysis, Joincare Pharmaceutical Group Industry Co (SHSE:600380) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥11.82, compared to a current price of ¥10.35 — trading 12.4% below its estimated fair value. The current EBIT per Share is ¥1.85. Joincare Pharmaceutical Group Industry Co's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Joincare Pharmaceutical Group Industry Co (SHSE:600380), the current EBIT per Share is ¥1.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joincare Pharmaceutical Group Industry Co (SHSE:600380) Overvalued in 2026?
Based on GuruFocus' analysis, Joincare Pharmaceutical Group Industry Co stock appears to be undervalued.
The current stock price of ¥10.35 is trading 12.4% below its estimated GF Value™ of ¥11.82.
GuruFocus considers Joincare Pharmaceutical Group Industry Co to be Modestly Undervalued.
Key valuation signals for SHSE:600380:
EBIT per Share: ¥1.85
GF Value™: ¥11.82 vs. price of ¥10.35 (12.4% below fair value)
No single metric tells the full story. See the SHSE:600380 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joincare Pharmaceutical Group Industry Co Ltd is an integrated pharmaceutical company, the business scope covers healthcare products, APIs, final dosage forms, prescription drugs, OTCs, Chinese traditional medicine, chemical drugs, and testing agents. APIs are antibiotic series and their intermediates 7ACA, 4AA and F9. Prescription drugs focus on the realms of the digestive tract, a blood vessel of heart and brain, infection, tumor, nervous cerebrovascular section, urinary system etc. OTCs include gastrointestinal drug Dele-Livzon, Live Bifidobacterium Preparation, oral ulcer drugs Yiketie, cold medicine Antiviral Oral Granule, External use skin medicine.
80GF Score
Get the complete analysis for SHSE:600380
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600380 has been successfully added to your 
